BRANFORD, Conn.--(BUSINESS WIRE)--A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples. In the study, the researchers performed ultra-deep amplicon sequencing of specific HLA class I and II gene loci with the Genome Sequencer FLX System and successfully assigned allele-level genotypes using software developed by Conexio Genomics. The results of the study have important implications for future research on a wide variety of human diseases and tissue transplantation.
